NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Xingruida XDR? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
65%
Finnrick rating
#372 of 498 ranked vendors
66 of 94 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Xingruida XDR's purity-focus record is best supported in Retatrutide and Tirzepatide, where many recent tests show repeated passes despite notable fill and purity misses. Results are dispersed: Ipamorelin is clean but sparse, while Tesamorelin, GHK-Cu, BPC-157 and TB-500 show uneven purity or quantity evidence with some batch-ID gaps.

methodology →
vendor intelligence report
Vendor Intelligence Report: Xingruida XDR

Corporate filings trace a dissolved UK namesake and a live Hong Kong layer without resolving the storefront’s controller. The report also maps shared-hosting overlap with Mammoth Biotech and a brand-keyword WhatsApp doorway network.

38 pages8 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$0.33
79%
24
2
Retatrutide
$0.99
78%
32
3
Ipamorelin
$0.90
73%
3
4
GHK-Cu
$0.08
70%
9
5
Melanotan II
$0.58
61%
2
6
PT-141
-
60%
3
7
Tesamorelin
$2.42
55%
10
8
BPC-157
$1.04
54%
8
9
TB-500
$1.74
43%
3
10
Cagrilintide
$3.38
-
0
12
Semaglutide
$2.14
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%22 Jan 2026: 63%22 Jan 2026: 63%4 Feb 2026: 63%4 Feb 2026: 63%9 Feb 2026: 62%11 Feb 2026: 63%11 Feb 2026: 63%15 Feb 2026: 64%18 Feb 2026: 63%18 Feb 2026: 63%26 Feb 2026: 63%26 Feb 2026: 64%2 Mar 2026: 63%6 Mar 2026: 64%7 Mar 2026: 62%13 Mar 2026: 62%8 May 2026: 61%13 May 2026: 61%15 May 2026: 61%25 May 2026: 61%27 May 2026: 61%27 May 2026: 61%27 May 2026: 63%27 May 2026: 62%5 Jun 2026: 63%16 Jun 2026: 63%30 Jul 2026: 63%3 Aug 2026: 63%3 Aug 2026: 63%9 Aug 2026: 64%9 Aug 2026: 64%9 Aug 2026: 64%12 Aug 2026: 65%12 Aug 2026: 65%12 Aug 2026: 65%12 Aug 2026: 65%12 Aug 2026: 65%12 Aug 2026: 65%20 Oct 2026: 65%30 Oct 2026: 65%14 Nov 2026: current 65%63%61%65%Jan 26Nov 26
Peptide testing

Ordered peptides from Xingruida XDR? Mail in a sample (US only) and let us test it.

Test my supply
Xingruida XDR test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
30 Oct 2026
Pass
Retatrutide
lab nameView COA
20 Oct 2026
Fail
Retatrutide
lab nameView COA
12 Aug 2026
Fail
Retatrutide
lab nameView COA
12 Aug 2026
Pass
Tirzepatide
lab nameView COA
12 Aug 2026
Pass
Retatrutide
lab nameView COA
12 Aug 2026
Pass
Tesamorelin
lab nameView COA
12 Aug 2026
Pass
Ipamorelin
lab nameView COA
12 Aug 2026
Pass
Tirzepatide
lab nameView COA
9 Aug 2026
Pass
Retatrutide
lab nameView COA
9 Aug 2026
Pass
TB-500
lab nameView COA
1-10 of 94

About Xingruida XDR test results from Finnrick

Xingruida XDR is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 94 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Xingruida XDR peptides in this dataset are BPC-157 (8 tests), GHK-Cu (9 tests) and Ipamorelin (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 94 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Xingruida XDR? Mail in a sample (US only) and let us test it.

Test my supply